Tirzepatide Duration: How Long Will You Be on Treatment?

Why there is no standard course length, and what that means in practice

A course of antibiotics lasts seven days. Tirzepatide does not work like that. The medicine addresses the biological drivers of weight gain (appetite signalling, gastric emptying, the hormonal cues that tell your brain the meal is over) and those drivers do not simply reset after a fixed number of injections. That is why the Mounjaro SmPC published on the electronic Medicines Compendium sets no upper time limit on treatment, and why NICE's appraisal of tirzepatide frames its recommendations around ongoing clinical monitoring rather than a stop date.

In practice, most people will use tirzepatide for at least 12 months. Some will continue for several years. Others will reach their weight goal, stabilise, and work with their prescriber to taper off, only to find that weight gradually returns, at which point restarting becomes a conversation. None of that is failure. It reflects how the medicine works and what obesity, as a chronic condition, actually requires.

The real question is not "how long is a course" but "what is the decision I need to make at each clinical review, and what information do I need to make it well". The sections below address the three factors that most influence that decision.

What happens to weight when tirzepatide stops, and why it matters for duration planning

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults over 72 weeks and recorded average body-weight reductions of around 20–21% at the 15 mg dose. What those headline figures cannot tell you is what happens next, and that matters enormously when you are deciding whether to stop.

Subsequent withdrawal studies across the GLP-1 class consistently show that a substantial proportion of lost weight returns within months of discontinuation. The biology that the medicine was correcting reasserts itself. This is not a personal shortcoming; it is pharmacology. Clinicians who understand this tend to plan for longer treatment windows from the outset, and to frame stopping as a transition that needs to be managed, not a clean exit.

The practical implication: if you are weighing up how long to stay on tirzepatide, your prescriber will want to know not just your current weight but your trajectory, are you still losing, holding steady, or have you plateaued? For more on what the published evidence says about results over time, the tirzepatide overview on this site covers the trial data in full.

Dose titration, plateaus and the timeline you should actually expect

Many people underestimate how gradual the therapeutic journey is. The 2.5 mg starting pen is not there to produce results; it gives your digestive system four weeks to adjust before the dose steps up. From there, titration typically continues in roughly four-week increments, 5 mg, then 7.5 mg, and so on toward the maintenance dose that suits you. Reaching a stable therapeutic dose can take four to six months on its own.

That means meaningful assessment of whether tirzepatide is working for you cannot happen at week eight. NICE's guidance notes that if weight loss is less than 5% after six months at the highest tolerated dose, continuing should be reviewed, a useful benchmark, but one that arrives well into the second half of your first year. Most people who are going to respond will be clearly doing so by that point.

Plateaus are normal and do not automatically mean the medicine has stopped working. A plateau during dose titration often resolves as the dose increases. A plateau at maintenance is worth discussing with your prescriber before drawing conclusions. If you are thinking about the practical side of managing a long course, including tirzepatide expiration windows, travelling with your pen, and what a missed week means, the preparation guide covers those details clearly. And for the question of how long the active compound stays in your system between injections, the separate duration of action page explains the pharmacokinetics in plain terms.

How duration interacts with cost, eligibility and ongoing review

Long-term treatment has real cost implications, and it would be dishonest to skirt that. If you are considering the private route, factoring in 12 or more months of ongoing treatment is part of the picture. The Mounjaro price comparison guide sets out what drives the variation in private pricing across the UK and what a legitimate single price should include, it is worth reading before committing to any provider.

On the NHS, tirzepatide is available under NICE's appraisal of tirzepatide (TA1026) for eligible adults through a phased rollout, but access depends on BMI thresholds, qualifying conditions and local commissioning, and for many people, the wait is long. Private treatment through a regulated online pharmacy is the practical alternative for those who meet the clinical criteria but cannot access NHS prescribing in a reasonable timeframe.

At nume, a GPhC-registered prescriber (a real clinician, not a form-routing system) re-assesses your case before each supply. Think of your pen sitting in the fridge door: it will not be refilled automatically. That review is the mechanism that keeps treatment clinically appropriate over months and years, adjusts for changes in your health, and makes duration a live decision rather than a passive slide. You can read more about how dosing options are structured, including what tirzepatide l involves, on the clinical team page, alongside how our clinical team approaches ongoing prescribing.

If you want to understand whether you are likely to be suitable and what ongoing treatment would look like, check your eligibility with a free consultation, there is no commitment, and a prescriber will give you a straightforward assessment.